about
Linear energy transfer distributions in the brainstem depending on tumour location in intensity-modulated proton therapy of paediatric cancerA comparison of three different adaptive strategies in image-guided radiotherapy of bladder cancer.Characterization of the optical properties and stability of Presageā¢ following irradiation with photons and carbon ions.Adaptive radiotherapy in locally advanced prostate cancer using a statistical deformable motion model.Adaptive plan selection vs. re-optimisation in radiotherapy for bladder cancer: a dose accumulation comparison.Normal tissue sparing in a phase II trial on daily adaptive plan selection in radiotherapy for urinary bladder cancer.An adaptive radiotherapy planning strategy for bladder cancer using deformation vector fields.Intra-fractional bladder motion and margins in adaptive radiotherapy for urinary bladder cancer.A comparison between two clinically applied plan library strategies in adaptive radiotherapy of bladder cancer.Conformal radiotherapy of urinary bladder cancer.Adaptive radiotherapy strategies for pelvic tumors - a systematic review of clinical implementations.A biological modeling based comparison of two strategies for adaptive radiotherapy of urinary bladder cancer.Relationships between dose to the gastro-intestinal tract and patient-reported symptom domains after radiotherapy for localized prostate cancerStatistical simulations to estimate motion-inclusive dose-volume histograms for prediction of rectal morbidity following radiotherapy.Imaging of normal lung, liver and parotid gland function for radiotherapy.Advances in radiotherapy: from 2D to 4D.Dosimetric verification of complex radiotherapy with a 3D optically based dosimetry system: dose painting and target tracking.Dose/volume-response relations for rectal morbidity using planned and simulated motion-inclusive dose distributions.The distance discordance metric-a novel approach to quantifying spatial uncertainties in intra- and inter-patient deformable image registration.An image-based method to quantify biomechanical properties of the rectum in radiotherapy of prostate cancer.Advancing our quantitative understanding of radiotherapy normal tissue morbidity.Radiation-induced cancer risk predictions in proton and heavy ion radiotherapy.Urinary bladder dose-response relationships for patient-reported genitourinary morbidity domains following prostate cancer radiotherapy.A method for evaluation of proton plan robustness towards inter-fractional motion applied to pelvic lymph node irradiation.A multiple-image-based method to evaluate the performance of deformable image registration in the pelvis.Risk of radiation-induced secondary rectal and bladder cancer following radiotherapy of prostate cancer.Biology-guided adaptive radiation therapy - presence or future?High-dose preoperative chemoradiotherapy in esophageal cancer patients does not increase postoperative pulmonary complications: correlation with dose-volume histogram parameters.Spatial rectal dose/volume metrics predict patient-reported gastro-intestinal symptoms after radiotherapy for prostate cancer.Semi-automated segmentation of the sigmoid and descending colon for radiotherapy planning using the fast marching method.Treatment planning studies in radiotherapy.Biology-guided adaptive radiotherapy (BiGART)--more than a vision?The normal tissue sparing potential of adaptive strategies in radiotherapy of bladder cancer.Treatment simulations with a statistical deformable motion model to evaluate margins for multiple targets in radiotherapy for high-risk prostate cancer.Biological dosimetry to assess risks of health effects in victims of radiation accidents: Thirty years after Chernobyl.Associations between volume changes and spatial dose metrics for the urinary bladder during local versus pelvic irradiation for prostate cancer.Intrafraction changes of prostate position and geometrical errors studied by continuous electronic portal imaging.CT-guided intensity-modulated radiotherapy for bladder cancer: isocentre shifts, margins and their impact on target dose.The on-going quest for treatment precision and conformality in radiotherapy.Outcome in intermediate or high risk prostate cancer patients receiving radiation dose and hormone therapy.
P50
Q30150151-566287AB-9A4A-413F-99E1-6A6AE4AD36CAQ33689907-DB8C2746-3CF9-4D80-B858-AD5F9749D9EFQ33964310-04456024-A4F9-470F-B070-20C5739B2D9AQ34960367-E8722FF9-6166-47ED-8E81-143F10914BD2Q35010599-4E244512-3478-4B44-8424-B7DE05E41CC7Q35193626-2C634B55-7D86-402D-91C3-FE99AB747211Q35230373-ABB62E95-D22A-49B0-9D84-A4382636A688Q35757353-B552B605-3A22-4748-96FB-97A4ABA905D8Q35844119-03D3189A-EF0E-4C00-AD87-C5571DF75706Q35978883-8F36277D-7E8E-468E-A660-BB0C6F0982F8Q35982957-208AD323-1D3C-4B18-88AA-170F3F51E7C6Q35995755-F13DE39C-A095-4538-842A-90CA9C6CF89AQ36672732-B19D25C4-B913-43BE-925D-05BFB489EE1AQ36770094-B6904AFC-719A-4A3A-BE8D-3875F4452BB4Q37787277-3EB1574E-33EC-454F-8812-86DAB929AF6EQ37970192-C59C6EC2-8CB3-4D22-A279-3F730BAC6265Q38424896-FF9E8299-3717-4116-AA5E-5585BFB0DC95Q38612461-74DD7E2C-6069-420D-B63A-AFFAAF07C42CQ38883068-C19D8BFB-2813-4CC6-B725-C8A16738C9C2Q38982334-20B14F32-FBCE-4E34-A629-3548B7888EAEQ39077895-F69CE93E-5350-41C6-84AC-A33761CF0D68Q39311892-6D13D274-A529-4D57-A952-08320871FFB1Q39995500-8D2D6DF5-D8B3-4BF9-8DFA-EBFBCF1CD1A5Q40704389-E6804F27-060B-49F9-AAD5-50F67C083DD2Q41453860-9713D483-9611-43EF-B759-1AA9121F4A09Q41526102-11AD4E7F-25EF-4714-A512-2B964415E403Q42910927-6FE5DA62-684D-47F3-9D82-928C66E789F8Q42937906-C7E27B0C-E6DC-4503-B0A5-770B2E44B5E7Q43365011-74470B07-93A2-4D59-9129-35505785E3D4Q44191431-C649B6E3-542F-4244-BC01-BE3C3E99CB40Q44731004-A362856A-0A8C-424E-B0AC-0A3254DFD7B3Q45122044-F4854430-7E47-47AA-83BF-E46FEC0A16A6Q45194876-514C11B2-631F-410A-98EE-D1B22F2E62C0Q45789217-8D819777-8502-4EEC-ACF5-6D4F6FD4E66BQ46319089-EA71D065-5C5E-4C82-8900-B88DA3354EBEQ46439191-8D2BA884-5157-460A-98F3-E57BAF99E0BBQ46457841-14BA45AA-B0E7-47F5-AAC4-613573E886D9Q46571949-0B7B516D-407F-41B4-9092-F19AA0DA669CQ46857800-45853121-34CD-4721-89C6-8EFB573290C6Q47673485-F56E18DD-3193-48D4-A95C-6CCD2F57C963
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
Õ°Õ„ÕæÕ”Õ¦ÕøÕæÕøÕ²
@hy
name
Ludvig P Muren
@ast
Ludvig P Muren
@en
Ludvig P Muren
@es
Ludvig P Muren
@nl
Ludvig P Muren
@sl
type
label
Ludvig P Muren
@ast
Ludvig P Muren
@en
Ludvig P Muren
@es
Ludvig P Muren
@nl
Ludvig P Muren
@sl
prefLabel
Ludvig P Muren
@ast
Ludvig P Muren
@en
Ludvig P Muren
@es
Ludvig P Muren
@nl
Ludvig P Muren
@sl
P106
P21
P214
221149294293280521450
P31
P496
0000-0002-7418-5832
P734
P735
P7859
viaf-221149294293280521450